Equity Research, Broker Reports, and media content on Circle

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Circle
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login
  • 16 Aug 17

AIM Breakfast

LoopUp—The provider of conference calls and online meetings is seeking to join AIM. 2015 revs of £9.2m and EBITDA of £1.02m | Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap | Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September | Autins Group plc - The acoustic and thermal insulation specialist now looks to join AIM late August

Companies: PEG COG IKA OMI EZH MMH IQG CIRC EPO

  • 22 Jun 17

Termination of coverage

Edison Investment Research is terminating coverage on Circle Holdings (CIRC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Companies: Circle
  • 01 Feb 17

Small Cap Breakfast

ADGORITHMS LTD| AFH FINANCIAL GROUP PLC | BYOTROL PLC | CHINA AFRICA RESOURCES PLC | CIRCLE HLDGS PLC | COAL OF AFRICA LTD | COHORT | EPWIN GROUP PLC | METMINCO LTD | QUANTUM PHARMA PLC

Companies: MNC PERE EPWN CHRT BYOT ALB CZA AFHP CIRC QP/

  • 09 Dec 16

Healthy options

Circle’s existing operations continued to progress in H116, with revenues ahead 6% year-on-year in H116 and both business units again generating positive EBITDA. The group EBITDA loss after central costs declined further and we estimate positive EBITDA for 2018. Management is focused on further diversifying the group offering and building the scale required to generate attractive overall returns. Already preferred bidder for a new musculoskeletal (MSK) contract in Greenwich, Circle seeks additional MSK contracts, has agreed an innovative entry into the Chinese healthcare market, and plans a new independent hospital in Birmingham and the introduction of medical rehabilitation services.

Companies: Circle
  • 16 Aug 16

AIM Breakfast

CAMBRIDGE COGNITION HLDGS PLC (COG LN) | CIRCLE HLDGS PLC (CIRC LN) | EARTHPORT PLC (EPO LN) | EASYHOTEL PLC (EZH LN) | ILIKA PLC (IKA LN) | MARSHALL MOTOR HLDGS PLC (MMH LN) | OROSUR MINING INC (OMI CN) | PETARDS GROUP (PEG LN) | ROXI PETROLEUM PLC (RXP LN) | UBISENSE GROUP PLC (UBI LN)

Companies: PEG COG IKA OMI CASP EZH MMH IQG CIRC EPO

  • 19 Oct 15

Growth in revenues and new opportunities

In H115, Circle Holdings (Circle) achieved revenue growth of 28% y-o-y so that EBITDA losses fell to 6.4% of revenue from 12% the year before. Circle does not feel it is under the same pressure on NHS work as its competitor Spire, because it relies less on block bookings for NHS contracts and more on individual choice. The result of the UK general election has reduced some of the political uncertainty that had affected the company and the UK health economy and it is actively bidding for new contracts. Circle has funding in place, in principle, to build a new hospital in Birmingham and planning approval was achieved in September. It has also just announced a joint venture to create an innovative proton beam treatment centre.

Companies: Circle

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Circle. We currently have 6 research reports from 2 professional analysts.

Open
N/A
Range Today
N/A
52 Week
14.0/31.5p
Daily Volume
N/A
# Shares
0m
Daily Liquidity
0.0%
Pension Liability
Enterprise Value
n/am
Market Cap
0m
Latest PE (hist)
Div Yield

Latest News/RNS

(more news)
Date Source Announcement
12May17 15:17 RNS Holding(s) in Company
03May17 14:17 RNS Rule 2.9 Announcement
03May17 10:26 RNS Holding(s) in Company
03May17 07:00 RNS Proposed cancellation of trading on AIM
03May17 07:00 RNS Bidco Compulsory Acquisition of Circle Shares
28Apr17 13:06 RNS Additional Listing
27Apr17 09:08 RNS Holding(s) in Company
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Circle

  • Providers covering

    Circle

  • 02 Dec 19

Acquisition – 7% accretive in first full year

SDI has announced the acquisition of Chell Instruments; paying c.£4.3m for the business (FY 2018 EV/Sales and EV/EBIT of 0.9x and 5.5x) funded from cash and a new debt facility with net debt at year-end now expected to be c.£5.0m. SDI has shown that it can source and execute another accretive acquisition in what was a competitive tender bid process. We expect the acquisition to be c.7% accretive to EPS in FY 2021 and raise our target price by 25% to 75p to reflect the accretion as well as rolling forward our target year, implying an EV/EBITDA of 11.9x and adjusted P/E of 17.3x.

Companies: Scientific Digital Imaging
  • 04 Dec 19

Cenkos: IXICO Plc -- Revenues growing and profitable

IXICO has reported a strong financial performance for FY19A built on continued commercial focus and a strengthened organisation. Revenues of £7.6m were up 40% and gross margin was up 600bps versus FY18A and the company delivered its first year of profitability since IPO. EBITDA of £0.5m was strongly ahead of our forecast (+£0.1m) and delivered an EBITDA margin of 6%. We have maintained our revenue growth expectations of 20% for FY20E and FY21E but have upgraded our profit expectations given the strong reported performance. We maintain our Buy recommendation.

Companies: IXICO
  • 06 Dec 19

H1 results: adjustments to clinical programmes

ReNeuron has announced its H1 2020 results; financials are slightly ahead of our expectations related to the identified slower recruitment of the Phase III PISCES trial. ReNeuron has made a number of positive clinical trial protocol changes to both the CTX and hRPC programmes to boost enrolment and accelerate clinical development, respectively, and we have included these changes into our forecasts.

Companies: Reneuron Group
  • 02 Dec 19

Cenkos: Creo Medical Group Plc - Cutting edge

Creo Medical continues to make strong progress on both development and commercial fronts. Following its direct entry into the US, the company recently reported its first commercial revenues from that market, building upon the broad commercial reach developed via its signed-up distributor network. While lead product, Speedboat, is making commercial progress, Creo expects to launch a further four endoscopic instruments on the CROMA Advanced Energy platform during 2020, significantly expanding the utility of the generator. To maintain this momentum, Creo Medical has announced it has conditionally raised £43m via an equity placing and will supplement this via an open offer to qualifying shareholders. We maintain our Buy recommendation.

Companies: Creo Medical Group
  • 21 Oct 19

Quarterly Research Outlook Autumn 2019

Following continued delays of a Brexit agreement, few sectors within the UK market have remained attractive to investors despite low valuations. One sector which has continued to outperform despite the political drama has been the UK video gaming sector (henceforth UK gaming), which we are fans of. We believe a combination of sector-leading growth, strong cash conversion and timely cyclical positioning support our positive view on the UK video gaming sector.

Companies: ABBY AMS ANX ARS ATYM AVON BLVN PIER BUR CGS CAML CDM CSRT TIDE CYAN DTG DEMG ELM EMR FPO FDEV GTLY GENL GHH GRI GEEC GKP HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KAPE KEYS KWS KCT KGH LAM LIT LOK MACF MANO MOD OXIG PCA PANR APP SRE PHC PMO RBW RMM RBGP REDD RSW RNO ROR SUS SCPA SEN SHG SOLG SOM SUMO TM17 INCE TWD TRAK TRI VNET VTC ZOO ZTF

  • 03 Dec 19

SP Angel Healthcare Conditions

Collagen Solutions (COS.L): Interim results | Genedrive plc (GDR.L): Hearing loss assay kit demonstrates high clinical accuracy

Companies: Collagen Solutions Genedrive

  • 05 Dec 19

US licensing deal: Major Opportunity Within LupuzorTM Unlocked

ImmuPharma announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals (“Avion”), a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps). Avion has exclusively in-licensed LupuzorTM for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed. We have always believed that ImmuPharma could deliver such a successful deal for the US market (given the track record of the previous deal executed with Cephalon). This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of LupuzorTM. We now see LupuzorTM as having the ability to generate blockbuster sales in the US (US$1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of US$170m per year. What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for LupuzorTM but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for LupuzorTM, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment. This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of LupuzorTM, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa. Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 76p to 100p / share. BUY.

Companies: ImmuPharma
  • 05 Dec 19

Avacta Group - Executive interview

In this video, Alastair Smith, CEO of Avacta Group, discusses the progress the company has made this year. This includes new and expanded partnerships, operational and financial achievements, and the advancement of AVA6000 towards the clinic.

Companies: Avacta Group
  • 04 Dec 19

Proving the accuracy and superiority of minibeams

The goal of Advanced Oncotherapy (AVO) is to deliver an affordable and more effective proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked through important technical milestones. AVO is now working on the verification and validation phase, prior to CE marking and LIGHT being used on the first patients. Meanwhile, AVO has entered into a research collaboration with the Cleveland Clinic aimed at proving the accuracy of targeting cancerous tissue, and sparing normal tissue, with proton minibeams in comparison with other methodologies.

Companies: Advanced Oncotherapy
  • 18 Jul 19

FY results; acquisitions to fully benefit FY 2020

Full-year results to 30 April 2019 were in line at the revenue line but 5% (£0.1m) better than expected at the adjusted pre-tax profit level. Underpinned by c.5.5% organic growth, the 20% and 26% increases in revenue and adjusted EBITDA were driven by full-year contributions from ATC and QSI, acquired in FY 2018, as well as five acquisitions in FY 2019. Notable was the 35% increase in free cashflow. Additional investments into Sentek, Atik, Graticules and Astles and the integration of ATC with Thermal Exchange in FY 2020 should benefit the businesses in FY 2021. We upgrade our FY 2020 adjusted EPS by 7% as well as introduce FY 2021 forecasts, which indicate 13% EPS growth. The company indicates that it expects to add at least one new business in FY 2020, which will be incremental to these forecasts. We are raising our target price by 9% to 60p, reflecting the improved gross margins and stronger underlying cashflow.

Companies: Scientific Digital Imaging
  • 01 Nov 19

Small Cap Feast

DNEG Limited One of the world's leading digital visual effects, animation and stereo conversion companies for feature film and television.The Offer will be comprised of new Shares to be issued by the Company (to raise expected gross proceeds of £150m). Admission is expected to take place in November 2019. Zaim Credit Systems— Zaim currently provides loans of up to Russian Roubles 30,000 (£375) to retail customers through its network of just over 95 sites predominantly in Moscow. Looking to raise £2.6m. Mkt cap £10.9m. Due 4th Nov. 2018 net interest £10.1m, PBT £835k.

Companies: THR CPT CCS INTO PPH PRM BST SAE LEK KDNC

  • 04 Nov 19

THE MONTHLY November 2019

The trade-off in the risk/reward for gold and gold mining equities is improving, as central banks push the current iteration of the post-World War II Bretton Woods financial order towards its limits.

Companies: AVO AJB AGY ARBB BUR CLIG DNL DPP FLTA GTLY GDR MCL MUR NSF PCA PIN SRE PHP RE/ RECI RMDL STX SCE TON SHED VTA W7L

  • 02 Dec 19

Interims – VISITECT CD4 starts to deliver on potential

Interim results were in line with the 22 October trading update, reflecting the financial benefits of closing its German business and selling the infectious disease business. Revenues from continuing operations increased 6% to £4.5m, largely reflecting the growth in Food Intolerance (+6% to £4.1m). This resulted in an adjusted EBITDA and pre-tax loss of c.£0.25m (vs. -£0.3m) and c.£0.35m (vs. -£0.5m), respectively. Omega also announced a further order from Nigeria for VISTECT CD4, which is contingent on approval in that market, but could be shipped by the FY year-end. We are not changing CD4 forecasts at this time until there is clarity over MoH approval. We make minor changes, however, to our FY forecasts to reflect the adoption of IFRS 16, which reduces adjusted pre-tax profits by c.£60k in both years. Year-end net debt is unchanged at c.£0.8m. We leave our target price unchanged at 25p.

Companies: Omega Diagnostics Group
  • 28 Nov 19

LIBERUM: Futura Medical* - December data could be game-changing

Futura is set to report headline data from its P3 FM57 study in erectile dysfunction (ED) in December. We believe that the trial is significantly de-risked and hence estimate a >70% probability of some form of positive outcome.

Companies: Futura Medical
  • 03 Dec 19

Cenkos: Collagen Solutions Plc -- Continued momentum

Collagen Solutions has reported results for the six-months to September 2019 (H1/20). As announced with the October Trading Update, revenues grew 14.4% to £2.23m for the period. Revenues were driven by the Core business which delivered 56% growth. The business acquired four new contracts and ten new customers during the period. The company remains engaged with its notified body in relation to ChondroMimetic, with the changing medical device regulatory environment limiting visibility on the timing of approval. We maintain our Buy recommendation.

Companies: Collagen Solutions